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Material and Methods: In vivo dosimetry was performed for 
40 HDR prostate brachytherapy patients treated with single 
fractions of 15Gy (boost) or 19Gy (monotherapy). Treatments 
were planned using intra-operative trans-rectal ultrasound 
(TRUS) and for in-vivo dosimetry, an additional needle was 
inserted centrally in the prostate gland and dose measured 
using a MOSFET. MOSFET measurements were compared to 
predicted readings based on exported treatment planning 
system (TPS) data, per-needle and for total plan dose. To 
assess impact of needle movement between planning TRUS 
and treatment, TRUS images were acquired immediately 
after treatment for 20 patients. To assess impact of 
heterogeneities (for example steel needles) on the dose at 
the MOSFET position Monte Carlo (MC) simulations of 
treatment plans were performed for 10 patients. A 
retrospective investigation of thresholds for real-time error 
detection was based on per-needle and total plan uncertainty 
analysis. Uncertainties included MOSFET 
calibration/commissioning results, source calibration, TPS, 
relative source/ MOSFET position and MOSFET reading 
reproducibility. 
 
Results: The mean measured total plan reading was 6.6% 
lower than predicted (range +5.1% to -15.2%). Plan 
reconstruction on post-treatment TRUS showed mean 
reduction in dose at the MOSFET position of 1.8% due to 
needle movement. MC simulations showed that 
heterogeneities caused a mean dose reduction at the MOSFET 
position of 1.6%. Uncertainty estimates varied between 
individual treatment plans, for example the uncertainty is 
higher if the MOSFET is close to a heavily weighted source 
position. Assuming a source/MOSFET position uncertainty of 
1mm, total plan dose uncertainty (k=2) ranged from 10.6% to 
17.0% and per needle dose uncertainty (k=2) ranged from 
18.2% to 110% (mean 31.0%). Retrospectively applying these 
uncertainty estimates as error detection thresholds resulted 
in 1 out of 40 plans and 5% of needles being outside the error 
detection threshold. The figure shows an example for one 
patient of predicted versus measured reading for each needle 
with the k=2 uncertainty illustrated by error bars.
 
 
Conclusion: In vivo measurements of dose during HDR 
prostate brachytherapy treatment delivery show good 
agreement with TPS predictions within measurement 
uncertainties, providing reassurance in the accuracy of dose 
delivery. Thresholds for real-time in vivo error detection 
using this measurement technique should be calculated on an 
individual plan basis but would still be likely to generate 
some false errors, with the main limitation of the 
measurement technique being that dose is only measured at 
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Purpose or Objective: Localized recurrent prostate cancer 
after primary radiotherapy can be curatively treated using 
salvage, including Iodine-125 brachytherapy (BT). Selection 
of patients for salvage is hampered by a lack of knowledge on 
predictive factors for cancer control, particularly in salvage 
BT. The aim of this study was to develop and internally 
validate a prediction model for biochemical failure (BF) after 
salvage I-125-BT using the largest cohort to date in order to 
aid patient selection in the future.  
 
Material and Methods: Patients with a clinically localized 
prostate cancer recurrence who were treated with a whole-
gland salvage I-125 implantation were retrospectively 
analyzed. Patients were treated in two centers in the 
Netherlands. Multivariable Cox-regression was performed to 
assess the predictive value of clinically relevant tumor-, 
patient- and biochemical parameters on BF, which was 
defined according to the Phoenix-definition (PSA-nadir+2 
ng/ml). Missing data was handled by multiple imputation (20 
datasets). The model’s discriminatory ability was assessed 
with Harrell’s C-statistic (concordance index). Internal 
validation was done using bootstrap resampling (using 2000 
resampled datasets). Goodness-of-fit of the final model was 
evaluated by visual inspection of calibration plots, after 
which individual survival was calculated for categories of the 
predictor variables from multivariable analysis. All analyses 
were performed using the recently published TRIPOD 
statement. 
 
Results: Sixty-two whole-gland salvage I-125-BT patients 
were identified. After median follow-up of 25 (range 0-120) 
months, 43 patients developed BF. In multivariable analysis, 
disease-free survival interval (DFSI) after primary therapy and 
pre-salvage prostate–specific antigen doubling time (PSADT) 
were predictors of BF; corrected hazard ratio (HR) 0.99 (95% 
confidence interval [CI]: 0.98-0.997 [p=0.01]) and 0.94 
(95%CI: 0.90-0.99 [p=0.01]), respectively. Calibration plots 
demonstrated accurate predictive ability up to 36 months. 
The adjusted C-statistic was 0.71. Of patients with a 
PSADT>30 months and DFSI>60 months, >70% remained free 
of recurrence until 3 years. With every 12 months increase in 
DFSI, PSADT can decrease with 3 months to obtain the same 
survival proportion (Figure 1).  
 
ESTRO 35 2016                                                                                                                                                    S29 
______________________________________________________________________________________________________ 
Conclusion: Salvage I-125-BT patients can be selected based 
on their disease free survival interval after primary therapy 
and the PSA-doubling time pre-salvage, ensuring sufficient 
biochemical control of >70% until three years. 
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Purpose or Objective: To report the incidence of second 
primary cancer ( SPC) after Iodine-125 brachytherapy for 
early prostate cancer in a single institution with an intense 
urological surveillance and to compare it with the cancer 
incidence in the Australian population 
 
Material and Methods: This retrospective, single-institution 
study included 889 patients treated with Iodine-125 
brachytherapy alone. All the patients had a baseline 
cystoscopy before the implant. Data were collected on all 
subsequent SPC diagnoses. SPC incidences were retrieved for 
all type of cancers and for cancers close to the radiation 
field. Interval since the implant was evaluated for potential 
association to the treatment. Standardized incidence ratios 
(SIRs) were calculated for all cancers and for bladder cancers 
and matched with the general population. The absolute 
excess risk (AER) was expressed in relation to 10000 persons-
years in the study. Kaplan-Meier analysis was used to 
determine the actuarial second malignancy and pelvic 
malignancy rates and the death from SPC and from any cause 
 
Results: Patients were followed for a median of 4.16 (0-12) 
years with 370 (42 %) patients having 5 years or more follow 
up. 62 % patients were older than 60 years. 61 patients (6.8%) 
subsequently developed a SPC with 12 pelvic malignancies : 8 
bladder and 4 rectal cancer. The 5- and 10- year cumulative 
incidences are 6.9% (95% Confidence Interval 5.0-9.4) and 
19% (95% CI 14-26) for any second malignancy, 1.3% (95%CI 
0.6-2.7) and 3.9% (95% CI 1.9-7.8) for any pelvic malignancy 
and 1% (95% CI 0.4-24) and 3.2% (1.4-7.1) for bladder cancer, 
respectively. The SIR was significantly higher for all pelvic 
malignancies at 2.10 (95% CI 1.09-3.67) and for all bladder 
cancers at 3.33 (95% CI 1.44-6.57). In the subgroup analysis 
bladder SPC risk was higher than expected for patients under 
60 years (SIR 6.52; 95%CI 1.3-19; AER 13) and within the first 
5 years of follow up (SIR 2.9 ; 95% CI 0.97-6.95; AER 10). 
Rectal cancer SIR were not significant or close in any of the 
categories. The 5- and 10-year rates of death from SPC were 
1.9 % (95% CI 1.0-3.5) and 9.1% (95% CI 5.2-16) and from any 
cause were 3.2% (95% CI 2-5 ) and 14.4% (95% CI 9.5-21.6). On 
multivariable analysis, older age was associated with 
increased SPC risk (HR 1.05, p=0.021) , all cause mortality 
(HR 1.13, p<0.001) and mortality due to SPC (HR 1.09, 
p=0.014). Smoking status was associated with all cause 
mortality (HR 2.15, p=0.026) and with mortality from second 
malignancy (HR 2.59, p=0.045) 
 
Conclusion: There may be an increased but small risk of 
second pelvic malignancy after prostate brachytherapy. A 
tendency towards a higher risk of bladder SPC after 
brachytherapy was found in the first 5 years of follow-up , 
probably resulting from screening bias . There was no 
significant increased rate of rectal cancer in any of the 
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Purpose or Objective: To determine the independent effect 
of additional intraoperative adaptive C-arm cone-beam 
computed tomography (CBCT) planning versus transrectal 
ultrasound (TRUS)-guided interactive planning alone in 
primary permanent I-125 brachytherapy for prostate cancer 
on long term biochemical disease free survival (bDFS). 
 
Material and Methods: All patients with biopsy proven 
T1/T2-stage prostate cancer treated with I-125 
brachytherapy were included in this cohort. Treatments were 
performed with TRUS-guided primary brachytherapy (+/- 
neoadjuvant hormonal therapy (NHT)) in a single institution 
in the period of November 2000 to December 2014. From 
October 2006 onwards, all patients received additional 
intraoperative adaptive CBCT planning for dosimetric 
evaluation and, if indicated, subsequent remedial seed 
placement in underdosed areas (which was performed in 15% 
of all patients). These procedures lasted 1-1.5 hours and 
were performed by a team of 2 radiation oncologists and 2 
therapeutic radiographers. Pre-operative characteristics, 
follow-up PSA and mortality were prospectively registered. 
Patients were stratified into National Comprehensive Cancer 
Network (NCCN) risk groups. Kaplan-Meier analysis was used 
to estimate bDFS (primary outcome), overall survival (OS) 
and prostate cancer specific survival (PCSS) (secondary 
outcomes). Cox-proportional hazard regression was used to 
assess the independent predictive value of CBCT use on 
biochemical failure (BF) (Phoenix definition) and overall 
mortality (OM). 
 
Results: 1623 patients were included. Median follow-up was 
99 months (interquartile range (IQR) 70-115) for TRUS 
patients (n=613) and 51 months (IQR 29-70) for CBCT patients 
(n=1010). BF occurred 203 times and 206 patients died, of 
which 26 due to prostate cancer. For TRUS and CBCT 
patients, estimated 7-year bDFS was 87.2% vs. 93.5% (log 
rank: p=0.04) for low risk patients, 75.9% vs. 88.5% (p<0.001) 
for intermediate risk patients and 57.1 vs. 85.0% (p<0.001) 
for high risk patients. For TRUS and CBCT patients with low, 
intermediate and high risk disease, estimated 7-year OS was 
respectively 86.5% vs. 90.4% (p=0.11), 79.6% vs. 85.1% 
(p=0.30) and 66.4% vs. 84.2% (p=0.01). For TRUS and CBCT 
patients, 7-year PCSS was 96.0% vs. 100% (p<0.0001). After 
Cox regression, CBCT patients had lower rates of BF: HR 0.45 
(95%-CI 0.33-0.61; p<0.0001). Corrected for age, IPSA, 
Gleason grade, T-stage, NHT-status and duration of NHT use, 
year of implantation, activity of the implant and prostate 
volume, CBCT showed to be an independent predictor of BF: 
HR 0.54 (95%-CI 0.33-0.89; p=0.02). CBCT was not an 
independent predictor of OM: HR 0.66 (95%-CI 0.40-1.07; 
p=0.09). 
 
Conclusion: Additional intraoperative adaptive C-arm cone-
beam CT planning in I-125 prostate brachytherapy leads to a 
significant increase in biochemical disease free survival in all 
NCCN risk groups.  
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Purpose or Objective: In adaptive radiotherapy, deformable 
image registration (DIR) is used for contour propagation and 
dose warping. Contour evaluation is visual and qualitative 
and only accurate in high contrast regions. Dose warping 
requires fully spatial and quantitative DIR evaluation 
measures also valid in low contrast regions. While 
